Kornimate/medical-research-clean huggingface dataset:
telerehabilitation in patients with fibrosing interstitial lung diseases

Conditions: Fibrosing Interstitial Lung Disease; Telerehabilitation

Summary: the aim of the study is to determine the effectiveness of different exercise programs applied to 3 groups randomly formed in patients with fibrosing interstitial lung disease (fild). secondary purpose: to determine the feasibility and effectiveness of telerehabilitation in fild cases.

the cases meeting the inclusion criteria will be randomized and divided into three groups, the groups will be named as telerehabilitation exercise group (tgr), video group (vgr) and standard pulmonary rehabilitation group (sgr).tgr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.after 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the vgr group, an exercise video including the exercises will be sent to participants and the patients will be asked to do exercises 3 days a week. the participants will be asked to keep an exercise diary and the status of the diaries will be followed by phone call once a week.the sgr group will be applied the pulmonary rehabilitation program with supervision in the hospital 2 days a week, and participants will be asked to do exercises at home for 1 day. the exercise period will be 8 weeks for both groups.details of the exercises to be applied to the cases are as follows: the exercise program includes aerobic, resistance exercises and breathing exercises.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-75 * have a diagnosis of fibrosing interstitial lung disease diagnosed according to the clinical diagnostic criteria of the american thoracic and european respiratory societies (ats-ers). * presence of dyspnea on exertion stable clinical state at the time of admission without infection or exacerbation in the previous 4 weeks * ability to use a smart phone exclusion criteria: * patients with severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases and needing high flow oxygen therapy (˃ 3-4 l \\min). * history of effort-related syncope or any comorbidity (such as severe orthopedic or neurological deficits or unstable heart disease) that precludes exercise training. * participating in a pulmonary rehabilitation program within the past 12 months.

Keywords: fibrosing interstitial lung disease telerehabilitation physiotherapy pulmonary rehabilitation
the role of polymerase chain reaction in the management of patients with infective endocarditis

Conditions: Endocarditis Infective

Summary: the aim of this study is to prospectively investigate the additional diagnostic value of broad range pcr targeting the 16 ribosomal dna in diagnosis and management of patients with infective endocarditis who are candidate for surgicaltherapy;

study protocol is divided into four different phases:screening, pre-operative clinical assessment (t-1), cardiac surgery (t0) and follow-up period (t4 et90). during the screening phase, patients will be assessed to determine whether they met the study inclusion/exclusion criteria. after signing the informed consent, patients will go through a preoperative clinical evaluation (t-1). the following assessments are carried out the day before surgery: recording patient's generality, present antibiotic therapy and possible results of blood cultures performed prior to recruitment; - twelve-lead ecg; - chest x-ray - transthoracic echocardiogram (tte); -. three pairs of blood cultures from three different blood sampling sites. in cases of complicated endocarditis, the presence and location of septic embolisms is recorded (using total body ct scan imaging), signs of heart failure evaluated and operability criteria are assessed. on the day of cardiac surgery (t0), main intraoperative data (valve findings, type of prosthesis, surgery time, cardiopulmonary bypass time and aortic cross clamping time) will be gathered; the excised valve was sent partly to the microbiology laboratory for culture and molecular tests and partly to the pathology laboratory. after cardiac surgery, patients continued to be monitored for a follow up at four (t4) and 90 (t90) days after surgery. during the follow-up period, information was collected on the patient's clinical status (vital parameters) and the antibiotic treatment performed. the same blood tests performed at t-1 are repeated at t4 and t90. all this data was recorded on a dedicated database.

Eligibility criteria:
inclusion criteria: 1. patients older than 18 years, with diagnosis of ie on a native or prosthetic valve and with a surgical indication for heart valve replacement using extracorporeal circulation (cpb). 2. patients who have signed informed consent to the partecipation of the study exclusion criteria: 1. patients younger than 18 years 2. failure to sign consent for personal data processing and/or study participation 3. participation in other experimental studies 4. patients who did not complete the examinations under study (culture test on blood and excised valve, molecular tests)
trial of jyb1904 in patients with allergic asthma

Conditions: Allergic Asthma

Summary: this phase iia trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of jyb1904 in patients with allergic asthma.


Eligibility criteria:
inclusion criteria: * able to provide written informed consent voluntarily; * aged 18-75 years, weight ≥ 40 kg, male or female; * diagnosed allergic asthma. exclusion criteria: * prior exposure to anti-ige therapy within 1 year; * allergic to anti-ige biologics; * current smokers, or quit smoking within 1 year; * combined with other non-allergic diseases that cause ige elevation； * history of malignancy, autoimmune diseases, immune complex mediated diseases, hypereosinophilic syndrome; * other conditions unsuitable for the trial judged by the investigator.
survey on supplement use in mitochondrial disease

Conditions: Mitochondrial Disease

Summary: the purpose of this study is to learn about the use of nutritional supplements in patients with mitochondrial disease.

our goal is to better assess which nutritional supplements are prescribed to patients with mitochondrial disorders, the monitoring obtained and whether any subjective improvements are noted by the patients or their caregivers.

Eligibility criteria:
inclusion criteria: * namdc clinical registry or rdcrn contact registry participant * diagnosis of a mitochondrial disease confirmed by either electron transport chain abnormalities or molecular testing. exclusion criteria: * lack of participation in namdc or rdcrn registries * diagnosis of mitochondrial disorder not confirmed by etc studies or molecular diagnosis
comparison of highly cross-linked and conventional polyethylene in total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: to our knowledge, there has been no information on in vivo clinical results of posterior cruciate-substituting arthroplasties using highly cross-linked polyethylene. we evaluated whether the clinical and radiographic results, incidence of post fracture of the tibial polyethylene insert, failure of the locking mechanism of the tibial polyethylene insert, and the incidence of osteolysis would be similar between posterior cruciate-substituting total knee prostheses using conventional and highly cross-linked polyethylene.


Eligibility criteria:
inclusion criteria: * osteoarthritis that was severe enough to warrant total knee arthroplasty after an adequate trial of nonoperative therapy, and the need for bilateral total knee arthroplasties exclusion criteria: * inflammatory arthritis * osteoarthritis of the hip causing pain or restricted mobility * a foot or ankle disorder which limited walking * dementia or a neurological disorder including a past history of stroke which affected mobility
the characterization of small and diminutive colonic polyps in lci

Conditions: Small Colon Polyps; Linked Color Imagimg; Diminutive Colon Polyps

Summary: colorectal cancer is a maior cause of morbidity and mortality worldwide.colonoscopy and removal of all adenomas is the most efficient method to prevent colorectal cancer.the most colorectal polyps detected are small(\<10mm) and diminutive(≦5mm) during colonoscopy.at that size,the are overwhelmingly hyperplastic or adenomatous,and rarely harbour high-grade dysplasia,cancer or sessile serrated adenoma/polyp.traditional white-light endoscopy cannot reliably distinguish between small adenomatous and hyperplastic polyps,thus,real-time recognition of the polyp histology during colonoscopy has the potential to minimize both the costs and complications associated with endoscopic biopsy and polpectomy.linked color imaging(lci),a new system for endoscopy modality,creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of magnifying blue laser imaging(bli) technology. it is easier to recognize a slight difference in color of the mucosa. this is a study to investigate the impact of linked color imaging endoscopes on the in vivo histology prediction of colonic polyps.

this is a prospective study comparing the accuracy of linked color imaging(lci) and standard white light colonoscopes in the diagnosis of small and diminutive colorectal polyps.

Eligibility criteria:
inclusion criteria: - 1.ability to provide written informed consent and undergoing colonoscopy. 2.the patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic work-up. 3.detection and retrieval for histologic examination of at least one polyp\< 10mm in size and/or 5mm in size exclusion criteria: * patients were previous colon resection * patients were a diagnosis of inflammatory bowel disease,familial polyp syndromes or poor bowel preparation * suspected chronic stricture potentially precluding complete colonoscopy * patients had polypectomy or had coagulopathy/thrombocytopenia * patients had diverticulitis or toxic megacolon;previous radiation therapy to the abdomen or pelvis;severe cardiovascular,pulmonary,liver,or renal disease;and coagulation disorders or use of anticoagulants. * all of polyps could influence surface pattern or/and color assessment
gluten free diet in people with schizophrenia: a pilot study

Conditions: Gluten Sensitivity; Celiac Disease

Summary: background: celiac disease is an immune-mediated reaction to gluten, presenting with diarrhea, weight loss, abdominal complaints and a range of less common associated neurologic and psychiatric symptoms. evidence of a link between schizophrenia and celiac disease dates back to 1961. recent evidence shows that 5.5% (age adjusted) of persons with schizophrenia participating in the clinical antipsychotic trials of intervention effectiveness (catie) study had a level of antibodies to ttg that is consistent with a diagnosis of celiac disease (compared to 1.1% of the comparison sample). an unexpected finding was that 23.4% (age adjusted) of the catie sample had antibodies to gliadin (compared to 2.9% of the comparison sample). it is hypothesized that a gluten free diet in people with schizophrenia who have celiac disease or gluten sensitivity will have improvement in symptoms and quality of life. objectives: the aim of this proposed pilot study is to establish the feasibility of a initiating and maintaining a gluten-free diet in these two groups. for this study the investigators will identify 8 individuals who have positive assays to ttg antibodies and confirmed celiac disease (n=4), or positive assays for anti-gliadin antibodies (n=4). the investigators plan to consent at least 2 subjects from each group and ask them to participate in a two-week open label treatment of a gluten free diet. the groups are; 1. celiac disease (positive ttg antibody); and 2. positive assay on antigliadin antibodies


Eligibility criteria:
inclusion criteria: * subjects will be of either gender and of any race, with an age range of 18 55. * subjects will meet dsm-iv (apa, 1994) criteria for either schizophrenia or schizoaffective disorder. a best estimate diagnostic approach will be utilized in which information from the structured clinical interview for dsm-iv (first et al, 1997) is supplemented by information from family informants, previous psychiatrists, and medical records to generate a diagnosis. * subjects will be required to have celiac disease (positive ttg antibody) or have gluten sensitivity (positive or aga antibodies). * must be clinically stable and on the same antipsychotic for at least two months with an unchanged dose for the prior four weeks. * participants must complete the evaluation to sign consent with a score of 10/12 or higher. exclusion criteria: * pregnant or lactating women will be excluded. pregnancy will be determined by pregnancy test. lactating will be determined by participant report.
investigation of female reproductive hormone dynamics during adolescence

Conditions: Menstruation Disturbances

Summary: irregular menstrual cycles are common in girls for several years after their first menstrual period. the cause of abnormal menstrual cycles during this time is not well-understood. the purpose of this study is to: 1) monitor girls during a menstrual cycle (with blood and urine sampling and serial pelvic ultrasounds) to identify those girls who do not ovulate (release of an egg from the ovary), and 2) determine whether cycles can be corrected by treating girls with a short course of low-dose estrogen and progesterone.


Eligibility criteria:
inclusion criteria: * no more than 3 ½ years postmenarchal exclusion criteria: * subjects currently on or previously treated with medications that may affect reproductive hormones (eg birth control pills). * subjects with severe acne or hirsutism * subjects who exercise excessively (running \> 20 miles/week or its equivalent) * subjects with any of the following medical conditions: diabetes, hypertension, hyperlipidemia, valvular heart disease, lupus, rheumatoid arthritis, migraine headaches with aura, undiagnosed breast mass, inflammatory bowel disease, gallbladder disease, sickle cell disease, or thrombophilia. * current smoker * history of deep venous thrombosis or pulmonary embolism in subject or first-degree relative
automated insulin delivery amongst pregnant women with type 1 diabetes

Conditions: Diabetes

Summary: evaluation of the biomedical and psychosocial impact of automated closed-loop (artificial pancreas) insulin delivery in women with type 1 diabetes during pregnancy

an open-label, multi-centre, randomized, two-arm parallel group trial comparing automated closed-loop and standard insulin delivery. 124 pregnant women between 18 and 45 years of age with type 1 diabetes of at least 12 months' duration on standard insulin delivery (csii or mdi) will be recruited through outpatient antenatal diabetes clinics. women fulfilling the eligibility criteria will be randomized to automated insulin delivery (aid) or to continue standard patient-directed insulin delivery (csii or mdi) without aid. the study will take place within the home and nhs antenatal clinical settings. additional blood samples for the research will be obtained at the 24th and 34th week of pregnancy and questionnaires will also be completed by the participant at the 34th week of pregnancy. following this we will collect information on the birth. 25 of the woman randomised to the closed loop insulin delivery system will also be interviewed to gain more information on, among other things, their existing diabetes management practices, everyday work and family lives and their experience with the device.

Eligibility criteria:
inclusion criteria: 1. between 18 and 45 years of age (inclusive). 2. a diagnosis of type 1 diabetes (t1d), as defined by who for at least 12 months. 3. a viable pregnancy confirmed by ultrasound, up to 13 weeks and 6 days gestation. 4. currently on intensive insulin therapy (≥3 injections or csii). 5. willingness to use the study devices throughout the trial. 6. hba1c level ≥48 mmol/mol (≥6.5%) at booking (first antenatal contact) and ≤86 mmol/mol (≤10%) at point of randomization. 7. able to provide informed consent. 8. have access to email. exclusion criteria: 1. non-type 1 diabetes. 2. any other physical or psychological disease which, in the opinion of the investigator, is likely to interfere with the normal conduct and interpretation of the study results e.g. untreated coeliac disease or untreated hypothyroidism. 3. current treatment with drugs known to interfere with glucose metabolism as judged by the investigator such as high dose systemic corticosteroids, non-selective beta-blockers and mao inhibitors. 4. known or suspected allergy against insulin. 5. women with advanced nephropathy (egfr \<45), severe autonomic neuropathy, uncontrolled gastroparesis or severe proliferative retinopathy, as judged by the investigator, that is likely to interfere with the normal conduct of the study and interpretation of study results. 6. very good or very poor glycaemic control i.e. first antenatal hba1c \ 10% (\>86 mmol/mol). women who enter pregnancy with hba1c \>10% (\>86 mmol/mol) may participate if they achieve hba1c ≤10% (≤86 mmol/mol) before randomization. 7. total daily insulin dose 1.5 iu/kg. 8. severe visual or hearing impairment. 9. unable to speak and understand english.

Keywords: type 1 diabetes
a study of 2-dose vaccination regimen of ad26.zebov and mva-bn-filo in infants

Conditions: Ebola Virus Disease

Summary: the purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing ad26.zebov (first vaccination; dose 1) and mva-bn-filo (second vaccination; dose 2) administered intramuscularly (im) on days 1 and 57, respectively (main study) and also to provide the heterologous 2-dose vaccination regimen (ad26.zebov on day 1 and mvabn-filo on day 57) to participants in the control arm of the main study (extension phase).


Eligibility criteria:
inclusion criteria: * parent(s) (preferably both if available or as per local requirements)/guardian must sign an informed consent form (icf) indicating that he or she understands the purpose of, and procedures required for the study, and potential risks and benefits of the study, and are willing to allow their child to participate in the study * parent(s)/guardian are willing/able to ensure that their child adheres to the prohibitions and restrictions * the parent(s)/guardian must be at or above the age of legal consent in the jurisdiction in which the study is taking place * infant must be healthy in the investigator's clinical judgment (and the parent(s)/guardian) on the basis of medical history, physical examination, vital signs and clinical laboratory tests performed at screening * infant has received all routine immunizations appropriate for his or her age at the time of enrollment as documented in the vaccination cards presented by the parent(s)/guardian. participants are allowed to catch up on routine immunizations if needed (support for beneficial vaccines may be offered to participants) * extension phase: prior enrollment in the control arm of the main study and did not withdraw consent, and receipt of at least the first vaccination (dose 1) in the main study exclusion criteria: * having received any candidate or other ebola vaccine * history of ebola virus disease (evd), or prior exposure to ebola virus, including travel to an area with a current ebola outbreak less than 1 month prior to screening * having received any experimental candidate ad26- or modified vaccinia ankara (mva)-based vaccine in the past * known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines \[for example, polysorbate 80, ethylenediaminetetraacetic acid (edta) or l-histidine for ad26.zebov vaccine; tris (hydroxymethyl)-amino methane (tham) for mva-bn-filo vaccine and neisseria meningitidis polysaccharide or tetanus toxoid for menacwy\]), including known allergy to chicken or egg proteins and aminoglycosides (gentamicin) * presence of acute illness (this does not include minor illnesses such as mild diarrhea or mild upper respiratory tract infection) or axillary temperature greater than or equal to (\>=) 37.5 degree celsius on day 1. participants with such symptoms will be excluded from enrollment at that time but may be rescheduled for enrollment at a later date * extension phase: having received any candidate or other ebola vaccine
clinical practice of inhalation anesthesia with sevoflurane in china

Conditions: Anesthesia, General

Summary: until recently, there was a lack of understanding and consensus among chinese anesthesiologists how they should practice general anesthesia with volatile anesthetics, since there was no standard of inhalation practice. in august 2011, the anesthesiology branch of the chinese medical association launched the first version of chinese consensus of standard clinical practice for inhalation anesthesia (consensus) in order to standardize the practice in china. the proposed registry is aimed to evaluate the current inhalation practice one year after the consensus has been released, and related patient outcome. this registry evaluated sevoflurane anesthesia, including screening, induction, maintenance, emergence, and follow-up within 24 hours post-operation.


Eligibility criteria:
inclusion criteria: 1. man or woman, aged from 18 to 70 years old. 2. american society of anesthesiologists (asa) physical status: i, ii and iii. 3. surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (lma). 4. the type of surgery is either general surgery, or orthopedics, or gynecology. 5. the duration of anesthesia ranges from 1 to 5 hours. exclusion criteria: 1. history of clinically significant cardiovascular, pulmonary, renal, hepatic or central nervous system or muscle disease. 2. known hypersensitivity or history of unusual response to any halogenated anesthetics. 3. personal or familial history of malignant hyperthermia. 4. female patients who are either pregnant or breast feeding. 5. general anesthesia is administered with total intravenous anesthesia (tiva) of propofol or sevoflurane maintenance combined with propofol continuous infusion during maintenance.

Keywords: economics, pharmaceutical physician's practice patterns chinese sevoflurane